Literature DB >> 33678554

Clostridioides difficile infection in patients with hematological malignancy: A multicenter study in Taiwan.

Yuan-Pin Hung1, Chin-Shiang Tsai2, Bo-Yang Tsai3, Pei-Jane Tsai3, Yuan-Ti Lee4, Jen-Chieh Lee2, Hsiu-Chuan Liu5, Po-Ren Hsueh6, Ching-Chi Lee7, Wen-Chien Ko8.   

Abstract

BACKGROUND: Among the individuals with hematological malignancy (HM) complicated with Clostridioides difficile infection (CDI), the variables associated with in-hospital mortality and recurrence of CDI were investigated.
MATERIAL AND METHODS: Including adults with HM and those without malignancy suffering from CDI from January 2015 to December 2016 in three hospitals in Taiwan.
RESULTS: Totally 314 patients including 77 with HM and 237 patients without malignancy were included. HM patients more often had low leukocyte counts (<500 cells/mL: 28.6% vs. 2.1%) than those without malignancy and more patients without malignancy had severe CDI than patients with HM (31.6% vs. 14.3%, P = .003), according to the severity score of IDSA/SHEA. Patients with HM had a higher recurrence rate of CDI (14.3%, 11/77 vs. 7.2%, 17/237; P = .07) and longer hospital stay (47.2 ± 40.8 days vs. 33.3 ± 37.3 days; P = .006) than those without malignancy. In the multivariate analyses for those with HM and CDI, the in-hospital mortality was associated with vancomycin-resistant Enterococcus (VRE) colonization or infection (odds ratio [OR] 7.72; P = .01), and C. difficile ribotype 078 complex infection (OR 9.22; P = .03). Moreover underlying hematological malignancy (OR 2.74; P = .04) and VRE colonization/infection (OR 2.71; P = .02) were independently associated with CDI recurrence.
CONCLUSION: Patients with HM complicated with CDI were often regarded as non-severe infection, but had a similar in-hospital mortality rate as those without malignancy. CDI due to ribotype 078 complex isolates heralded a poor prognosis among HM patients.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Clostridioides difficile infection; Hematologic malignancy; Leukocyte count; Recurrence; Severity

Mesh:

Year:  2021        PMID: 33678554     DOI: 10.1016/j.jmii.2021.02.002

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  6 in total

1.  Clinical Significance of Toxigenic Clostridioides difficile Growth in Stool Cultures during the Era of Nonculture Methods for the Diagnosis of C. difficile Infection.

Authors:  Ching-Chi Lee; Jen-Chieh Lee; Chun-Wei Chiu; Pei-Jane Tsai; Wen-Chien Ko; Yuan-Pin Hung
Journal:  Microbiol Spectr       Date:  2021-10-20

2.  Clostridium butyricum therapy for mild-moderate Clostridioides difficile infection and the impact of diabetes mellitus.

Authors:  Jen-Chieh Lee; Chun-Wei Chiu; Pei-Jane Tsai; Ching-Chi Lee; I-Hsiu Huang; Wen-Chien Ko; Yuan-Pin Hung
Journal:  Biosci Microbiota Food Health       Date:  2021-11-03

3.  Neutrophil Ratio of White Blood Cells as a Prognostic Predictor of Clostridioides difficile Infection.

Authors:  Ching-Chi Lee; Jen-Chieh Lee; Chun-Wei Chiu; Pei-Jane Tsai; Wen-Chien Ko; Yuan-Pin Hung
Journal:  J Inflamm Res       Date:  2022-03-19

4.  Impacts of Corticosteroid Therapy at Acute Stage of Hospital-Onset Clostridioides difficile Infections.

Authors:  Ching-Chi Lee; Jen-Chieh Lee; Chun-Wei Chiu; Pei-Jane Tsai; Wen-Chien Ko; Yuan-Pin Hung
Journal:  Infect Drug Resist       Date:  2022-09-10       Impact factor: 4.177

5.  Effect of Doxycycline in Decreasing the Severity of Clostridioides difficile Infection in Mice.

Authors:  Bo-Yang Tsai; Yi-Hsin Lai; Chun-Wei Chiu; Chih-Yu Hsu; Yi-Hsuan Chen; Yueh-Lin Chen; Pei-Jane Tsai; Yuan-Pin Hung; Wen-Chien Ko
Journal:  Antibiotics (Basel)       Date:  2022-01-17

6.  The Role of Toll-Like Receptor-2 in Clostridioides difficile Infection: Evidence From a Mouse Model and Clinical Patients.

Authors:  Yi-Hsin Lai; Bo-Yang Tsai; Chih-Yu Hsu; Yi-Hsuan Chen; Po-Han Chou; Yueh-Lin Chen; Hsiao-Chieh Liu; Wen-Chien Ko; Pei-Jane Tsai; Yuan-Pin Hung
Journal:  Front Immunol       Date:  2021-07-12       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.